Noile-Immune Biotech Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	3,743	3,918	4,670	5,555	4,520	4,140
Cash & Short-Term Investments	3,743	3,918	4,670	5,555	4,520	4,140
Cash Growth	-16.17%	-16.10%	-15.93%	22.90%	9.18%	62.48%
Other Receivables	30	26	62	66	-	53
Receivables	30	26	62	66	-	53
Inventory	1	2	8	20	3	4
Prepaid Expenses	18	21	29	38	27	25
Other Current Assets	25	16	6	38	34	3
Total Current Assets	3,817	3,983	4,775	5,717	4,584	4,225
Long-Term Investments	27	28	24	61	56	45
Other Long-Term Assets	-	-	1	-	1	1
Total Assets	3,844	4,011	4,800	5,778	4,641	4,271
Accounts Payable	-	-	-	1	-	-
Accrued Expenses	31	31	27	29	45	20
Current Income Taxes Payable	25	39	32	48	235	51
Other Current Liabilities	5	4	10	8	55	9
Total Current Liabilities	61	74	69	86	335	80
Other Long-Term Liabilities	6	6	7	6	7	6
Total Liabilities	67	80	76	92	342	86
Common Stock	4,047	4,047	4,047	4,045	2,787	2,537
Additional Paid-In Capital	4,025	4,025	4,025	4,023	2,765	2,515
Retained Earnings	-4,300	-4,147	-3,353	-2,389	-1,259	-872
Comprehensive Income & Other	5	6	5	7	6	5
Shareholders' Equity	3,777	3,931	4,724	5,686	4,299	4,185
Total Liabilities & Equity	3,844	4,011	4,800	5,778	4,641	4,271
Net Cash (Debt)	3,743	3,918	4,670	5,555	4,520	4,140
Net Cash Growth	-16.17%	-16.10%	-15.93%	22.90%	9.18%	62.48%
Net Cash Per Share	86.44	90.48	107.86	133.96	115.40	108.06
Filing Date Shares Outstanding	43.3	43.3	43.3	43.3	39.58	38.31
Total Common Shares Outstanding	43.3	43.3	43.3	43.3	39.58	38.31
Working Capital	3,756	3,909	4,706	5,631	4,249	4,145
Book Value Per Share	87.23	90.78	109.09	131.33	108.60	109.23
Tangible Book Value	3,777	3,931	4,724	5,686	4,299	4,185
Tangible Book Value Per Share	87.23	90.78	109.09	131.33	108.60	109.23